Novellus Systems Newswire (Page 3)

Novellus Systems Newswire (Page 3)

Comprehensive Real-Time News Feed for Novellus Systems. (Page 3)

Results 41 - 60 of 82 in Novellus Systems

  1. Cowen and Company Reaffirms "Outperform" Rating for Nivalis Therapeutics IncRead the original story w/Photo

    Mar 6, 2016 | AmericanBankingNews.com

    's stock had its "outperform" rating reaffirmed by Cowen and Company in a note issued to investors on Tuesday, Analyst Ratings.Net reports. The analysts wrote, "Nivalis reported a Q4 net loss of $6.6MM and ended 2015 with a cash balance of."

    Comment?

  2. Nivalis Therapeutics' (NVLS) "Outperform" Rating Reiterated at Cowen and CompanyRead the original story w/Photo

    Mar 1, 2016 | AmericanBankingNews.com

    's stock had its "outperform" rating reiterated by analysts at Cowen and Company in a note issued to investors on Tuesday, Marketbeat.com reports. The analysts wrote, "Nivalis reported a Q4 net loss of $6.6MM and ended 2015 with a cash balance of."

    Comment?

  3. Nivalis Therapeutics Inc (NVLS) Stake Reduced by Jennison AssociatesRead the original story w/Photo

    Feb 20, 2016 | AmericanBankingNews.com

    Jennison Associates cut its position in shares of Nivalis Therapeutics Inc by 4.4% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 551,546 shares of the company's stock after selling 25,639 shares during the period.

    Comment?

  4. Applied Materials, Nivalis & Nordstrom Lead Thursday's After-Hours MoversRead the original story

    Feb 18, 2016 | Benzinga

    U.S. equities see-sawed during Thursday's trading session but ended near the session lows. The Dow Jones lost 0.25 percent to close at 16,413.22, the S&P 500 lost 0.47 percent to close at 1,917.82 while the Nasdaq index was an under-performer as it lost 1.03 percent to close at 4,487.54.

    Comment?

  5. Nivalis Therapeutics Announces FDA Fast Track Designation for N91115 in Patients With Cystic FibrosisRead the original story w/Photo

    Feb 18, 2016 | GlobeNewswire

    Nivalis Therapeutics, Inc. , a clinical stage pharmaceutical company focused on developing innovative solutions for people with cystic fibrosis , today announced the U.S. Food and Drug Administration has granted Fast Track designation for the Company's lead investigational drug, N91115, a novel stabilizer of the cystic fibrosis transmembrane conductance regulator protein. "We are very pleased to announce the FDA's Fast Track designation, as this status is intended to facilitate the development and expedite the review of important new treatments, like N91115, that stand to help people living with serious conditions like CF," said Jon Congleton, president and chief executive officer of Nivalis.

    Comment?

  6. U.S. IPO Weekly Recap: IPO Market Largely Closed; 2 Biotechs Go Public And BreakRead the original story w/Photo

    Feb 13, 2016 | Seeking Alpha

    The IPO market was poised to raise $1.4 billion from four IPOs this past week, but instead two biotechs raised $145 million. A substantial portion of those proceeds came from insiders, and both biotechs broke issue with an average loss of 17%.

    Comment?

  7. Massachusetts-Based Proteostatis Therapeutics IPO: Early Stage And...Read the original story w/Photo

    Feb 10, 2016 | Seeking Alpha

    Despite large potential demand, PTI is still in Phase I trials and faces enormous competition . Proteostatis Therapeutics Incorporated expects to raise $50.0 million in its upcoming IPO.

    Comment?

  8. Massachusetts-Based Proteostatis Therapeutics IPO: Early Stage And...Read the original story w/Photo

    Feb 10, 2016 | The US Market Blog

    Despite large potential demand, PTI is still in Phase I trials and faces enormous competition . Proteostatis Therapeutics Incorporated expects to raise $50.0 million in its upcoming IPO.

    Comment?

  9. Brokerages Expect Nivalis Therapeutics Inc (NASDAQ:NVLS) to Announce ($0.38) EPSRead the original story w/Photo

    Feb 9, 2016 | Daily Political

    Shares of Nivalis Therapeutics Inc have been given an average broker rating score of 1.00 from the four brokers that provide coverage for the stock, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy rating.

    Comment?

  10. Activist Investor Latches On to MarvellRead the original story w/Photo

    Feb 3, 2016 | Light Reading

    An investment company with a track record of packaging distressed technology companies for sale revealed it has accumulated a significant minority stake in Marvell Technology. Starboard Value filed a 13-D form notifying the Securities and Exchange Commission that it now owns 6.7% of Marvell Technology Group Ltd. 's stock, or over 34 million shares.

    Comment?

  11. Brokerages Expect Nivalis Therapeutics Inc (NASDAQ:NVLS) to Announce ($0.34) Earnings Per ShareRead the original story w/Photo

    Jan 19, 2016 | AmericanBankingNews.com

    Nivalis Therapeutics Inc has received a consensus broker rating score of 1.00 from the four brokers that provide coverage for the stock, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy rating.

    Comment?

  12. Nivalis Therapeutics Announces FDA Orphan Drug Designation for N91115 in Cystic FibrosisRead the original story w/Photo

    Jan 15, 2016 | GlobeNewswire

    Nivalis Therapeutics, Inc. , a clinical stage pharmaceutical company focused on developing innovative solutions for people with cystic fibrosis , today announced the U.S. Food and Drug Administration has granted Orphan Drug Designation to the Company's lead investigational drug, N91115, a novel stabilizer of the cystic fibrosis transmembrane conductance regulator protein. "The Orphan Drug Designation represents an important milestone in the development and regulatory strategy for N91115 and underscores the unmet need that remains in treating CF," said Jon Congleton, president and chief executive officer of Nivalis.

    Comment?

  13. Will Apple Drive Analog ICs?Read the original story w/Photo

    Jan 11, 2016 | Design And Reuse

    Analog expert Stephan Ohr turns his oscilloscope on the possible impact Apple could have with its new fab in San Jose. No one outside Apple knows what the iPhone giant will do with the 70,000-square foot analog production line it recently purchased from Maxim.

    Comment?

  14. This comment is waiting for review by our moderators.Read the original story w/Photo

    Jan 11, 2016 | EETimes

    Analog expert Stephan Ohr turns his oscilloscope on the possible impact Apple could have with its new fab in San Jose. No one outside Apple knows what the iPhone giant will do with the 70,000-square foot analog production line it recently purchased from Maxim.

    Comment?

  15. LifeVantage Appoints New Board Members to Board of DirectorsRead the original story w/Photo

    Jan 8, 2016 | GlobeNewswire

    ... at GaSonics, Mr. Toole led the company's initial public offering in 1994 and the sale of the company to Novellus Systems in 2001. Mr. Toole began his career at Advance Micro Devices, a manufacturer of early computer chips, where he was a production ...

    Comment?

  16. Analysts Expect Nivalis Therapeutics Inc (NASDAQ:NVLS) to Post ($0.34) EPSRead the original story w/Photo

    Jan 1, 2016 | AmericanBankingNews.com

    Nivalis Therapeutics Inc has been assigned an average broker rating score of 1.00 from the four analysts that provide coverage for the stock, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy recommendation.

    Comment?

  17. Jon Congleton Purchases 5,000 Shares of Nivalis Therapeutics Inc (NVLS) StockRead the original story w/Photo

    Dec 14, 2015 | AmericanBankingNews.com

    Nivalis Therapeutics Inc CEO Jon Congleton acquired 5,000 shares of the firm's stock in a transaction dated Friday, December 11th. The shares were bought at an average cost of $8.10 per share, with a total value of $40,500.00.

    Comment?

  18. Zacks: Nivalis Therapeutics Inc (NASDAQ:NVLS) Given $27.33 Consensus Target Price by BrokeragesRead the original story w/Photo

    Dec 14, 2015 | AmericanBankingNews.com

    Nivalis Therapeutics Inc has earned a consensus broker rating score of 1.00 from the four brokers that provide coverage for the company, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy recommendation.

    Comment?

  19. Nivalis Therapeutics Inc (NVLS) Position Sold by Monashee Investment ManagementRead the original story w/Photo

    Dec 11, 2015 | AmericanBankingNews.com

    Monashee Investment Management sold its position in Nivalis Therapeutics Inc during the third quarter, according to its most recent disclosure with the SEC. The institutional investor previously had a 62,500 share position in the company, valued at approximately $495,625.

    Comment?

  20. Nivalis Therapeutics Inc's Lock-Up Period Will End on December 14thRead the original story w/Photo

    Dec 6, 2015 | AmericanBankingNews.com

    Nivalis Therapeutics' lock-up period will end on Monday, December 14th. Nivalis Therapeutics had issued 5,500,000 shares in its IPO on June 17th, AnalystRatings.Net reports.

    Comment?